ABRAXANE

Peak

paclitaxel

NDAINTRAVENOUSPOWDER
Approved
Jan 2005
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20

Mechanism of Action

depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions. Paclitaxel induces abnormal arrays or "bundles" of microtubules throughout the cell cycle and multiple…

Pharmacologic Class:

Microtubule Inhibitor

Clinical Trials (5)

NCT07433673Phase 2Recruiting

Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)

Started Aug 2026
20 enrolled
Colon and Rectal Cancer
NCT07362186Phase 3Not Yet Recruiting

LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma

Started Apr 2026
NCT07445295Phase 3Not Yet Recruiting

Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Started Mar 2026
NCT07290140N/ANot Yet Recruiting

Paclitaxel-Coated Balloon Treatment of Chronic Rhinosinusitis

Started Mar 2026
NCT07432594Phase 2Not Yet Recruiting

Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer

Started Mar 2026

Loss of Exclusivity

LOE Date
Jul 12, 2034
101 months away
Patent Expiry
Jul 12, 2034

Patent Records (5)

Patent #ExpiryTypeUse Code
8268348
Feb 21, 2026Expired
U-1290
9101543
Feb 21, 2026Expired
U-1434
7758891
Feb 21, 2026Expired
U-1434
8034375
Aug 13, 2026
U-1290
9101543*PED
Aug 21, 2026